Welcome to the EASD e-Learning Newsflash. We are reporting our scientific highlights from the ATTD 2026, kicking off the diabetes conference season with a focus on advanced technologies and treatments. As tradition prescribes, ATTD initiator and co-chair Moshe Phillip opened Thursday’s scientific programme with the “hot from the oven” session. The auditorium was packed because people who come to this meeting are really interested in what's new. It's now about how to cure. The gene therapy session, when to use early intervention in type 2 diabetes, that was another lecture showing that early intervention, early aggressive intervention, if you might call it, have better chance to cope with the risk factors and prevent them earlier in the process. I think that we are now in an effort to define when does type 2 diabetes actually start and when is the best time to intervene and what is the best intervention. Another lecture was about a decision-support system given directly to people with diabetes. They got an advice that they are not alone. They got an advice of how to titrate in between the visits and also a warning if there is any reason to warn them. The advancement of CGM remains a key area of research. Editor-in-chief of Diabetes Technology and Therapeutics, Satish Garg, presented on the frequency use of CGM in the management of type 2 diabetes in a session he co-chaired. The study that I presented here was a retrospective study that included a retrospective study that included about 75,000 people who were prescribed the CGM. This was one cohort. In the second cohort, there was about 10,000 patients we looked at versus a control group. The most important part in this study was we compared the group of people who were in the control group that were given the GLP analogues versus those who were not using the CGM but were given the GLP analogues. People who were not given the CGM, they also dropped by about 0.8 % from baseline. But when you look at the group who were using both GLP and CGM, the drop was close to 2 %. So more than a one and a half times drop in HbA1c. We now turn our attention to another rapidly advancing area in diabetes tech, as we’ll hear from EASD Board member Julia Mader who presented on using apps for the management of type 2 diabetes. We do have different types of apps that we can use. So for example, we have apps that help us to track glucose. In most cases those are in connection with CGM devices. Otherwise, we do have also motivational apps that help people to stay on track when it comes to their medication or their behaviour. And then we have coaching apps where they can get tips and tricks how to best handle their diabetes. The most effective apps are apps that do not only track glucose, but that also give us support and provide coaching at the same time. And there is one German app that was developed by the team around Professor Schwarz from Leipzig and that is also the only app that is currently considered a DiGa, so a digital help health application in the German system and that's even reimbursed. What are the key challenges and limitations regarding app based interventions? So one of the challenges is that we should define if we want to have an app that's also considered a CE-marked or otherwise approved clinical device, or if it's just like a gadget, and number two, then reimbursement factors may arise. Ending on a positive note, what opportunities do you see for apps? Speaking of apps that are also becoming medical devices, what we see also out of data coming from my hometown Graz, there is a small start-up that started to develop an app for the inpatient diabetes management, but now they're moving along to the outpatient care and here we do see that there are benefits when it comes to glucose control, when it comes to self-sustainedness of the diabetes nurses or the home care nurses because for them it's helpful if they have some guidance where they can work independently without needing to call a physician. And number three, it has a positive impact also on the healthcare system because in many cases those people under home care would then be sent to the hospital or to the acute care facilities for their deterioration in glucose control, and with that app based kind of intervention they can improve their glucose control under the guidance of the nurse and the system. That’s it for today. Join us tomorrow for our Friday highlights from ATTD 2026 with co-chair Tadej Battelino, Lia Bally and EASD President Francesco Giorgino.